9 4 3 6 4
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
维生素 D 代谢酶的 CYP24A1-rs2296241 多态性与同激素相关的癌症风险之间的关联：一项综合分析
Authors Wang P, Zhang HM, Zhang ZL, Qin LQ, Li BY
Published Date May 2015 Volume 2015:8 Pages 1175—1183
DOI http://dx.doi.org/10.2147/OTT.S80311
Received 4 January 2015, Accepted 24 March 2015, Published 22 May 2015
Background: The evidence for vitamin D reducing cancer risk is inconsistent, and it
is not clear whether this reduction is related to variation in cytochrome P450
(CYP)24A1, the only enzyme known to degrade active vitamin D. We focused on
evaluating the association of CYP24A1-rs2296241 polymorphism with
hormone-related cancer risk by conducting a meta-analysis.
Methods: A systematic literature search was conducted in April 2014 (updated in December 2014) to identify eligible studies. A random-effects model was used to pool the odds ratio (OR).
Results: Eleven studies including 5,145 cases and 5,136 controls were considered for the allelic model, and eight studies of 3,959 cases and 3,560 controls were utilized for the additive, recessive, and dominant models. There was no significant association between CYP24A1-rs2296241 and hormone-related cancer risk in any of the models, yet substantial heterogeneity was observed. Subgroup analyses indicated that CYP24A1-rs2296241 variation reduced the prostate cancer risk in the additive (OR 0.91, 95% confidence interval 0.85–0.97) and recessive (OR 0.80, 95% confidence interval 0.67–0.95) models, with no evidence of heterogeneity.
Conclusion: This meta-analysis indicated that CYP24A1-rs2296241 polymorphism reduced the androgen-related prostate cancer risk in additive and recessive models. More genetic loci are needed to confirm the effect of CYP24A1 variation on the risk of prostate cancer.
Keywords: CYP24A1, hormone-related cancer, meta-analysis, polymorphism, vitamin D
Methods: A systematic literature search was conducted in April 2014 (updated in December 2014) to identify eligible studies. A random-effects model was used to pool the odds ratio (OR).
Results: Eleven studies including 5,145 cases and 5,136 controls were considered for the allelic model, and eight studies of 3,959 cases and 3,560 controls were utilized for the additive, recessive, and dominant models. There was no significant association between CYP24A1-rs2296241 and hormone-related cancer risk in any of the models, yet substantial heterogeneity was observed. Subgroup analyses indicated that CYP24A1-rs2296241 variation reduced the prostate cancer risk in the additive (OR 0.91, 95% confidence interval 0.85–0.97) and recessive (OR 0.80, 95% confidence interval 0.67–0.95) models, with no evidence of heterogeneity.
Conclusion: This meta-analysis indicated that CYP24A1-rs2296241 polymorphism reduced the androgen-related prostate cancer risk in additive and recessive models. More genetic loci are needed to confirm the effect of CYP24A1 variation on the risk of prostate cancer.
Keywords: CYP24A1, hormone-related cancer, meta-analysis, polymorphism, vitamin D
